Live Breaking News & Updates on Meeting Of The Society Hematologic Oncology

Stay updated with breaking news from Meeting of the society hematologic oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

A Look Into Selecting TKIs for CML Treatment

Given the wealth of available options, the selection of tyrosine kinase inhibitors for patients with chronic myeloid leukemia is faced with a plethora of nuanced decisions. ....

United States , Michael Deininger , College Of Wisconsin , Meeting Of The Society Hematologic Oncology , Versiti Blood Research Institute , Annual Meeting , Hematologic Oncology , Medical College , Cathy White Endowed Chair , Versiti Blood Research , Society Hematologic Oncology , Patients With Chronic Myeloid Leukemia , Medical College Of Wisconsin ,

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene. ....

United States , Avapritinib Ayvakit , Prithviraj Bose , Midostaurin Rydapt , International Working Group , American Society Of Hematology Annual Meeting , University Of Texas Md Anderson Cancer Center , International Consensus Classification Of Myeloid Neoplasms , Blueprint Medicines Corp , Touchstone Sm Patient , Iwg Myeloproliferative Neoplasms Research , European Competence Network On Mastocytosis , World Health Organization Classification Of Haematolymphoid Tumours , World Health Organization , Meeting Of The Society Hematologic Oncology , International Consensus Classification , Myeloid Neoplasms , European Competence Network , Annual Meeting , Hematologic Oncology , Cancer Center , Myeloproliferative Neoplasms Research , Cogent Biosciences , Hematology Annual Meeting , Acute Leukemias , World Health Organization Classification ,

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment. ....

Mayo Clinic In Rochester , United States , Angela Dispenzieri , Meeting Of The Society Hematologic Oncology , Department Of Molecular Medicine , Division Of Clinical Biochemistry , International Myeloma Working Group , Department Of Internal Medicine , Department Of Laboratory Medicine , Division Of Hematology , Annual Meeting , Hematologic Oncology , Sagar Lonial , Internal Medicine , Clinical Biochemistry , Laboratory Medicine , Molecular Medicine , Mayo Clinic , Myeloma Working Group , Blood Cancer , Smoldering Multiple Myeloma ,

TKI Selection in CML Demands Nuanced Approaches

Choosing the most effective TKIs for individual patients with chronic myeloid leukemia requires decision making based on efficacy data, agent safety profiles, and patient characteristics, according to Michael Deininger, MD. ....

United States , Michael Deininger , Society Of Hematologic Oncology , Meeting Of The Society Hematologic Oncology , Versiti Blood Research Institute , Bristol Myers Squibb , Annual Society , Hematologic Oncology , Rational Choice , Annual Meeting , Society Hematologic Oncology , Kinase Inhibitor Trial , Chronic Myeloid Leukemia , Year Update , Optic Trial , Dose Optimization Study , Patients With Chronic Myeloid Leukemia ,

Considerations for CAR T-Cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.
....

United States , Carona Jacobson , Juno Bristol Myers Squibb , Dana Farber Cancer Institute , Meeting Of The Society Hematologic Oncology , Effector Cell Therapy Program , European Hematology Association , International Conference On Malignant Lymphoma , Immune Effector Cell Therapy Program , Hematology Association , Bristol Myers Squibb , Malignant Lymphoma , Annual Meeting , Society Hematologic Oncology , Non Hodgkin Lymphoma , Follicular Lymphoma , Cart Cell , 2023 Soho Annual Meeting ,